Mission Pharmacal launches pair of Rx cough medicines

SAN ANTONIO — Mission Pharmacal Company recently announced the launch of Hycofenix (hydrocodone bitartrate, pseudoephedrine hydrochloride, and guaifenesin) oral solution. Mission has also announced the launch of Flowtuss (hydrocodone bitartrate and guaifenesin) oral solution. The combination of clinically proven ingredients in Flowtuss offers relief of two cough and cold symptoms.

 

"Mission Pharmacal is pleased to offer multi-action Hycofenix and Flowtuss to the medical community to fulfill an unmet healthcare need in the cough and cold therapeutic area," stated Ron Scalf, VP pharmaceutical sales, Mission Pharmacal. "In just one prescription, Hycofenix effectively relieves the cough, loosens respiratory secretions for a more productive cough, and clears nasal congestion. For the patient that does not need the nasal decongestant, Flowtuss effectively relieves the cough and loosens respiratory secretions for a more productive cough."

 

Hycofenix effectively relieves three cough and cold symptoms in just one prescription. Hycofenix is the first and only combination of hydrocodone, pseudoephedrine and guaifenesin approved by the U.S. Food and Drug Administration. These three clinically proven ingredients provide triple action and targeted relief from symptoms associated with the common cold.

 

Both products are available in black raspberry flavor and have been approved by the FDA for use in patients 18 years of age and older.

 

In preparation for this launch, Mission has expanded its sales force and increased promotional efforts to reach more primary care and internal medicine healthcare providers across the United States. All team members have completed extensive training related to cough and cold therapeutic needs, as well as pharmacy stocking and administrative needs for products containing hydrocodone, which is classified as a Schedule II, narcotic based, anti-tussive.

 

"To support customer needs related to Hycofenix and Flowtuss, we have nearly doubled the size of our sales team," said John McLaughlin, sales director, primary care division, Mission Pharmacal. "We are excited that the addition of these products in a new therapeutic class enables us to grow and better serve primary care providers and their patients." 

 

Mission has invested in many programs that will help patients quickly obtain Hycofenix or Flowtuss at an affordable price. Through partnerships, Mission provides value-added programs to healthcare providers, pharmacies and patients. These include retail partner pharmacy stocking support, coupons and discounts and email notifications about product availability.

 

"Based on initial market research and evaluation, we learned that healthcare providers are very interested in products that contain an expectorant in their combination therapy. Both of our products contain guaifenesin, an expectorant to help loosen respiratory secretions for a more productive cough," commented Dawn Garvin, product manager for Hycofenix and Flowtuss, Mission Pharmacal. "We are excited to introduce these two products that will offer relief for patients that suffer from specific symptoms during the cough and cold season."